Radiotherapy/Radiation Cancer Research Results

Rad, Radiotherapy/Radiation: Click to Expand ⟱
Features:
Treatment of disease with radiation, especially by selective irradiation with x-rays or other ionizing radiation and by ingestion of radioisotopes.

Radiosensitizer
Atorvaqone, (mitochondria inhibitor) decrease O2 consumption making more O2 available as a radiosensitizer.
-Hypoxia (low oxygen levels) within tumors is a major cause of resistance to radiotherapy


Scientific Papers found: Click to Expand⟱
4614- SSE,  Rad,    Updates on clinical studies of selenium supplementation in radiotherapy
- Review, Nor, NA
*toxicity∅, Risk↓, *selenoP↑, *ROS↓, *DNAdam↓, *QoL↑, *radioP↑, *Dose↝,
5078- SSE,  Rad,    Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer
- Trial, Pca, NA
Half-Life↝, OS↑, Pain↓, PSA↓, GSH↓, ROS↑, selectivity↑, TumCG↓, AR↓, Dose↑, ChemoSen↑, RadioS↑,
5079- SSE,  Rad,    The solvent and treatment regimen of sodium selenite cause its effects to vary on the radiation response of human bronchial cells from tumour and normal tissues
- in-vitro, Lung, A549 - in-vitro, Nor, BEAS-2B
chemoP↑, eff↝, ROS↑, MMP↓, Cyt‑c↑, TumCG↓, RadioS↝, other↝,
4739- SSE,  Chemo,  Rad,    Therapeutic Benefits of Selenium in Hematological Malignancies
- Review, Var, NA
ChemoSen↑, radioP↑, QoL↑, Risk↓, *selenoP↑, TumCP↓, Inflam↓, ChemoSen↑, TumCCA↑, Apoptosis↑, angioG↓, Dose⇅, ROS↑, eff↑, Risk↓, eff∅, CSCs↓, ROS↑,
4750- SSE,  Rad,    Selenium in Radiation Oncology—15 Years of Experiences in Germany
- Review, Var, NA
RadioS∅, radioP↑, eff↑,
2118- TQ,  Rad,    In vivo radioprotective effects of Nigella sativa L oil and reduced glutathione against irradiation-induced oxidative injury and number of peripheral blood lymphocytes in rats
- in-vivo, Nor, NA
*ROS↓, RenoP↑, hepatoP↑,
4859- Uro,  Rad,    Urolithin A Enhances Tight Junction Protein Expression in Endothelial Cells Cultured In Vitro via Pink1-Parkin-Mediated Mitophagy in Irradiated Astrocytes
- in-vitro, Nor, NA
*ROS↓, *VEGF↓,
4616- VitA,RetA,  VitC,  VitD3,  VitE,  Rad  Vitamins and Radioprotective Effect: A Review
- Review, Var, NA
*radioP↑, *ROS↓,
6894- VitC,  Rad,    Pharmacological Ascorbate as a Means of Sensitizing Cancer Cells to Radio-Chemotherapy While Protecting Normal Tissue
- Review, Var, NA
AntiTum↑, selectivity↑, H2O2↑, RadioS↑, radioP↑, ChemoSen↑, ROS↑, DNAdam↑,
4887- ZER,  Rad,  Cisplatin,    Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma
- in-vitro, HNSCC, CAL27
Apoptosis↑, ChemoSen↑, RadioS↑, tumCV↓,

Showing Research Papers: 151 to 160 of 160
Prev Page 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 160

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NA↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   Catalase↓, 1,   cystine↓, 1,   GPx↑, 1,   GPx4↓, 1,   GSH↓, 8,   GSH/GSSG↓, 1,   H2O2↑, 2,   HO-1↓, 1,   lipid-P↑, 2,   NRF2↓, 2,   NRF2↑, 2,   ROS↓, 2,   ROS↑, 41,   SOD↓, 1,   SOD2↓, 1,   TBARS↑, 1,   Thiols↓, 1,   Trx↓, 1,   TrxR↓, 3,   xCT/SLC7A11↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ADP:ATP↓, 1,   mtDam↑, 1,   OCR↑, 1,   p‑PDH↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 1,   ALDOA↓, 1,   AMPK↑, 1,   ATP↓, 2,   ECAR↓, 3,   GAPDH↓, 1,   glucose↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 2,   HK1↓, 1,   HK2↓, 1,   lactateProd↓, 2,   NADPH↑, 1,   PDK1 / PDPK1↓, 1,   PDKs↑, 1,   PKM2↓, 1,   PPP↑, 1,   Pyruv↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,   Apoptosis↑, 23,   BAX↓, 1,   BAX↑, 4,   Bax:Bcl2↑, 1,   Bcl-2↓, 6,   Bcl-xL↓, 1,   Casp3↑, 8,   cl‑Casp3↑, 1,   Casp8↑, 1,   Casp9↑, 4,   Cyt‑c↑, 2,   Ferroptosis↑, 1,   ICD↑, 1,   p38↑, 2,   p‑p38↑, 1,   survivin↓, 1,   TumCD↑, 4,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 2,   Akt↑, 1,   p‑Akt↓, 3,   EGFR↓, 1,   ERK↓, 2,   ERK↑, 1,   p‑ERK↓, 1,   JNK↓, 1,   JNK↑, 1,   MAPK↓, 1,   mTOR↓, 1,   PI3K↓, 2,   PI3K↑, 1,   RAS↑, 1,   STAT3↓, 1,   p‑STAT3↓, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

p‑FOXO3↓, 1,   HATs↓, 1,   HDAC↓, 1,   OCT4↓, 1,   other?, 1,   other↓, 1,   other↑, 1,   other↝, 3,   Prot↓, 1,   SOX2↓, 1,   tumCV↓, 6,  

Protein Folding & ER Stress(tgid=8) ⓘ

ER Stress↑, 1,   HSP70/HSPA5↑, 1,   HSP90↓, 2,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   TumAuto↑, 4,  

DNA Damage & Repair(tgid=10) ⓘ

8-oxo-dG↓, 1,   BRCA2↓, 4,   DNAdam↓, 2,   DNAdam↑, 10,   DNArepair↓, 5,   P53↑, 4,   P53↝, 1,   PARP↓, 1,   cl‑PARP↑, 2,   PCNA↓, 1,   γH2AX↑, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 1,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 1,   Ki-67↓, 1,   mitA↑, 1,   P21↓, 1,   TumCCA↓, 1,   TumCCA↑, 17,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   ALDH1A1↓, 1,   CSCs↓, 3,   Diff↑, 1,   EIF4E↓, 1,   Ki-67↓, 1,   mTORC1↓, 1,   TumCG↓, 8,   TumCP?, 1,   TumCP↓, 15,  

Migration(tgid=13) ⓘ

Cav1↓, 1,   EMT↓, 2,   MMP2↓, 2,   MMP9↓, 2,   TGF-β↓, 2,   TumCI↓, 4,   TumCMig↓, 5,   TumMeta↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 7,   Hif1a↓, 5,   Hypoxia↓, 3,   VCAM-1↓, 1,   VEGF↓, 4,  

Barriers & Transport(tgid=15) ⓘ

EPR↑, 2,   MMP↓, 7,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD44↓, 1,   COX2/PTGS2↓, 4,   Gal-3↓, 1,   HMGB1↑, 1,   IL1β↓, 2,   IL6↓, 2,   Imm↑, 4,   Inflam↓, 4,   Inflam↑, 1,   MCP1/CCL2↓, 1,   NF-kB↓, 5,   NF-kB↑, 1,   p‑NF-kB↓, 1,   PSA↓, 1,   RANTES↓, 1,   TNF-α↓, 2,  

Cellular Microenvironment(tgid=17) ⓘ

pH↝, 1,   e-pH↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AKR1C3/17β-HSD5/PGF Synthase↓, 1,   AR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 2,   ChemoSen↑, 12,   ChemoSen∅, 1,   CompStab↑, 1,   Dose?, 1,   Dose↓, 1,   Dose↑, 3,   Dose⇅, 1,   Dose↝, 24,   Dose∅, 1,   eff↓, 3,   eff↑, 13,   eff⇅, 1,   eff↝, 3,   eff∅, 1,   Half-Life↝, 1,   RadioS?, 2,   RadioS↓, 3,   RadioS↑, 85,   RadioS↝, 1,   RadioS∅, 1,   selectivity?, 1,   selectivity↓, 1,   selectivity↑, 19,   Synergy↑, 5,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   BloodF↑, 4,   CRP↓, 1,   EGFR↓, 1,   IL6↓, 2,   LDH↝, 1,   NLR↓, 1,   PSA↓, 1,   RBC↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   antiD↑, 1,   AntiTum↑, 3,   AntiTum∅, 1,   ANXi↓, 1,   chemoP↑, 5,   CR↑, 2,   fatigue↓, 1,   fatigue∅, 1,   hepatoP↑, 1,   hepatoP↝, 1,   LC↑, 2,   Mucositis↓, 2,   NKG2D↑, 1,   OS↑, 12,   Pain↓, 4,   QoL↑, 2,   radioP?, 1,   radioP↑, 21,   RenoP↑, 1,   Risk↓, 4,   toxicity↓, 2,   toxicity↝, 2,   TR↑, 1,   TumVol↓, 3,   TumW↓, 1,   Weight↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

GutMicro↑, 1,  
Total Targets: 221

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 5,   Catalase↑, 3,   GPx↑, 3,   GPx1↑, 2,   GPx4↑, 1,   GSH↓, 1,   GSH↑, 6,   GSH/GSSG↑, 1,   HO-1↑, 2,   Iron↓, 1,   lipid-P↓, 2,   MDA↓, 2,   MDA↑, 1,   NOX4↓, 1,   NRF2↓, 1,   NRF2↑, 5,   Prx↑, 1,   ROS↓, 22,   ROS∅, 1,   selenoP↑, 4,   SOD↑, 5,   SOD1↑, 1,   TAC↑, 1,   Trx↑, 1,   TrxR1↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

compI↑, 1,   compIII↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ATP↑, 1,   glucose↝, 1,   NADPH↑, 1,   NADPH∅, 1,   PGC1A↑, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,   Apoptosis↑, 1,   BAX↓, 1,   Bcl-2↑, 1,   Casp3↓, 3,   cl‑Casp3↓, 1,   p‑p38↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 1,   p‑Akt↑, 1,   ERK↓, 1,   ERK↑, 1,   JNK↓, 1,   Mst1↓, 1,   STAT3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

p‑cJun↓, 1,   DNMTs↓, 1,   HDAC↑, 1,   other↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 7,   P53↓, 1,   SIRT6↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

p300↓, 1,  

Migration(tgid=13) ⓘ

AP-1↓, 1,   Ca+2↓, 1,   Ca+2↑, 1,   Rho↓, 2,   ROCK1↓, 3,   TGF-β↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

VEGF↓, 1,   VEGF↑, 1,  

Barriers & Transport(tgid=15) ⓘ

IBI↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 2,   DR4↓, 1,   ICAM-1↓, 2,   IL10↑, 1,   IL1β↓, 2,   Inflam↓, 7,   MCP1/CCL2↓, 1,   NF-kB↓, 3,   p‑NF-kB↓, 1,   NLRP3↓, 1,   RANTES↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

ACE/ACE1↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 8,   eff↑, 1,   eff↝, 1,   Half-Life↝, 1,   RadioS↑, 1,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

BUN↓, 1,   LDH↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cognitive↑, 2,   hepatoP↑, 1,   Learn↑, 1,   memory↑, 1,   OS↑, 1,   QoL↑, 1,   radioP↑, 24,   toxicity?, 1,   toxicity↓, 6,   toxicity↝, 1,   toxicity∅, 1,   Weight↑, 1,   Wound Healing↓, 1,   Wound Healing↑, 1,  
Total Targets: 100

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:201  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page